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Background:  Balancing the reduction in ischemic events and bleeding complications with antithrombotic agents (ATA) in patients with non-ST-
segment elevation myocardial infarction (NSTEMI) managed invasively remains challenging in clinical practice. Recent clinical trials have offered 
insights into selection of ATA.
Methods: We analyzed trends in use of ATA in 64,199 NSTEMI patients (n=100 sites) managed invasively with cardiac catheterization from 2007 
to 2010 in the ACTION Registry®-GWTGTM. ATA included unfractionated heparin (UFH), low molecular weight heparin (LMWH), glycoprotein IIb/IIIa 
inhibitors (GPI) and bivalirudin (Biv). Unadjusted rates (median %) of ATA use, excess dosing, in-hospital mortality and bleeding events are presented 
(Figure 1).
Results: From 2007 to 2010, a consistent increase in the use of Biv and decline in the use of GPI was observed despite no change in the 
proportion of patients treated with PCI within 48 h of hospital arrival (51.0% vs 51.8%, p=0.19). Excess dosing of UFH (81.1% vs 58.9%, p<0.0001) 
and GPI (8.4% vs 5.4%, p<0.0001) also declined significantly over this time period. Although in-hospital mortality remained unchanged (2.2% vs 
1.9%, p=0.08), there was a significant decline in the rate of major bleeding (9.1% vs 6.8%, p<0.0001).
Conclusion:  In the past 4 years, NSTEMI patients managed invasively are receiving less GPI and LMWH and more UFH and Biv, with better dosing 
accuracy as well. Mortality rates remained stable, but rates of major bleeding have improved.
 
